Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

Inclusion criteria: * Fasting TG 500-2000 mg/dL (off of TG-lowering medications-see below) * Age 35-75 years Exclusion criteria: * Use of Lovaza (2g/d or more) or high-dose dietary supplement omega-3 oil (4g/d or more) in the past 2 months * Use of lipid therapy (statin, ezetimibe, fibrate, BAS, or niacin at therapeutic dose, 1g/d or higher) in the past 3 weeks (washout of prior therapy permitted) * Anticipated need to change type or dose of BP medicine (all types allowed), of lipid-active diabetes medication (thiazolidinedione), of oral estrogen (BCP or HRT), or glucocorticoid during the study (16 + 2 weeks = 18 weeks total) * Excess ethanol consumption (regular intake \>4 drinks/d, or binges of \>8 drinks at once for men, half these levels for women) * Poorly controlled diabetes mellitus (A1c \>9%) * History of acute or chronic pancreatitis * Use of exenatide (Byetta) or sitagliptin (Januvia), medications believed to increase the risk of acute pancreatitis * History of significant unexplained or uncontrolled bleeding or bruising * Poorly controlled blood pressure (\>140/90mmHg, with or without treatment) * Poorly controlled thyroid disease (TSH outside of normal range) * Hepatic disease (ALT \> 2.5x ULN, Dx of hepatitis or cirrhosis) * Any contraindication or prior adverse reaction to Lovaza * Active cancer (except basal cell or squamous cell skin cancer) * Pregnancy, plan/desire to become pregnant, breast feeding * Inability or unwillingness to provide informed consent